Fecal Calprotectin Levels Dynamics in Newborns with High-Risk of Necrotizing Enterocolitis

Background. Necrotizing enterocolitis (NEC) is severe gastrointestinal disease in newborns, its early clinical symptoms are nonspecific. Fecal сalprotectin (Cp) is considered as one of the early biomarkers of NEC, thus, its use in newborns is poorly known.

Objective. The aim of the study is to evaluate clinical significance of fecal Cp measuring as an early NEC marker in newborns. Methods. The prospective cohort observational study included high-risk newborns (gestational age (GA) ˂ 33 weeks and/or body weight ˂ 1500 g) and moderate risk newborns (GV≥ 33 weeks at suspicion on NEC) of NEC admitted to the neonatal intensive care unit on the 1st day of life. The Cp level was studied via immune colorimetric method on the 3rd and 7th days of life in high-risk children and in all children at NEC manifestation. All patients were divided into 2 main subgroups after the end of the follow-up period: newborns with developed NEC (a) and children without NEC (b). Obtained Cp values were compared between these subgroups.

Results. There were no statistically significant differences in Cp levels at the 3rd and 7th days of life in the high-risk group of children with NEC and without NEC. However, it was noted that children without NEC showed a decrease in Cp levels on the 7th day, while children with NEC manifestation, indeed, had increased levels. Cp levels did not differ in the moderate risk group.

Conclusion. Single measurement of Cp level in newborns of any GA is uninformative towards the NEC prognosis and diagnosis. However, evaluation of the Cp level dynamics at the 7th day of life compared to the 3rd day of life may be considered as a promising non-invasive method for prognosis of NEC manifestation in premature infants (GA<33 weeks). 

1. Singh DK, Miller CM, Orgel KA, et al. Necrotizing enterocolitis: Bench to bedside approaches and advancing our understanding of disease pathogenesis. Front Pediatr. 2023;10:1107404. doi: https://doi.org/10.1053/j.sempedsurg.2008.07.004

2. Neu J. Necrotizing enterocolitis. World Rev Nutr Diet. 2014;110:253–263. doi: https://doi.org/10.1159/000358474

3. Nikitina IV, Donnikov AE, Krogh-Jensen OA, et al. Genetic predictors of necrotizing enterocolitis in neonates. Obstetrics and Gynecology. 2020;(12):150–158. (In Russ). doi: https://doi.org/10.18565/aig.2020.12.150-158

4. Castellanos MW, Claud EC. The microbiome, guard or threat to infant health. Trends Mol Med. 2021;27(12):1175–1186. doi: https://doi.org/10.1016/j.molmed.2021.08.002

5. Hunter CJ, Upperman JS, Ford HR, et al. Understanding the susceptibility of the premature infant to necrotizing enterocolitis (NEC). Pediatr Res. 2008;63(2):117–123. doi: https://doi.org/10.1203/pdr.0b013e31815ed64c

6. Gregory KE, Deforge CE, Natale KM, et al. Necrotizing enterocolitis in the premature infant: neonatal nursing assessment, disease pathogenesis, and clinical presentation. Crit Care Med. 2011;11(3):155–164. doi: https://doi.org/10.1097/anc.0b013e31821baaf4

7. Yoon JM, Park JY, Ko KO, et al. Fecal calprotectin concentration in neonatal necrotizing enterocolitis. Korean J Pediatr. 2014;57(8):351– 356. doi: https://doi.org/10.3345/kjp.2014.57.8.351

8. Josefsson S, Bunn SK, Domellof M. Fecal calprotectin in very low birth weight infants. J Pediatr Gastroenterol Nutr. 2007;44(4):407– 413. doi: https://doi.org/10.1097/mpg.0b013e3180320643

9. Mussap M, Noto A, Cibecchini F, et al. The importance of biomarkers in neonatology. Semin Fetal Neonatal Med. 2013;18(1):56–64. doi: https://doi.org/10.1016/j.siny.2012.10.006

10. Dale I, Brandtzaeg P, Fagerhol MK. et al. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes: immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol. 1985;84(1):24–34. doi: https://doi.org/10.1093/ajcp/84.1.24

11. Bohnhorst B. Usefulness of abdominal ultrasound in diagnosing necrotising enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2013;98(5):F445–F450. doi: http://doi.org/10.1136/archdischild-2012-302848

12. Hanai H, Takeuchi K, Iida T, et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci. 2004;49(9):1438–1443. doi: https://doi.org/10.1023/b:ddas.0000042243.47279.87

13. Goold E, Pearson L, Johnson LM. Can fecal calprotectin serve as a screen for necrotizing enterocolitis in infants? Clin Biochem. 2020;84:51–54. doi: https://doi.org/10.1016/j.clinbiochem.2020.06.015

14. Campeotto F, Elie C, Rousseau C, et al. Faecal calprotectin and gut microbiota do not predict enteropathy in very preterm infants. Acta Paediatr. 2021;110(1):109–116. doi: https://doi.org/10.1111/apa.15354

15. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1–7. doi: https://doi.org/10.1097/00000658-197801000-00001

16. Walsh MC, Kliegman RM. Necrotizing Enterocolitis: Treatment Based on Staging Criteria. Pediatr Clin North Am. 1986;33(1):179– 201. doi: https://doi.org/10.1016/s0031-3955(16)34975-6